The short version of Stenabolic fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white solid | Visual inspection is not sufficient for identity. |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water. |
| Typical storage | -20 °C, desiccated, dark | Protect from repeated temperature changes. |
| Common analytical method | LC-MS or HPLC-UV | Reference standard required for comparison. |
| Common synonyms | SR9009; Stenabolic; REV-ERB agonist | Vendor naming may vary. |
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
The major pathways of human exposure to MNPs are inhalation, ingestion and dermal contact, with bioaccumulation varying based on particle size, composition, and physicochemical characteristics. Research suggests that MNPs above 150 μm typically remain confined to tissues and do not enter systemic circulation, whereas particles below 200 nm can breach cellular and tissue barriers, potentially reaching the bloodstream and other organs. This diversity in bioaccumulation pathways underscores the widespread yet nuanced risks of MNP exposure to human health. These findings collectively suggest that MNPs may accumulate in multiple organ systems depending on the exposure route, potentially leading to long-term health consequences as their presence in human tissues builds up over time.
R3N + 3 H2 → 3 RH + H3N R2S + 2 H2 → 2 RH + H2S Hydrogenolysis can be applied to the conversion of virtually any functional group into hydrocarbons. Substrates include haloalkanes, alcohols, aldehydes, ketones, carboxylic acids, etc. Both hydrogenolysis and hydrogenation are practiced in refineries. They can be effected by using lithium aluminium hydride, Clemmenson reduction and other specialized routes.
whereas if the integral is greater than one the disease will not die out and there may be such resonances. For example, considering the periodically varying contact rate as the 'input' of the system one has that the output is a periodic function whose period is a multiple of the period of the input. This allowed to give a contribution to explain the poly-annual (typically biennial) epidemic outbreaks of some infectious diseases as interplay between the period of the contact rate oscillations and the pseudo-period of the damped oscillations near the endemic equilibrium. Remarkably, in some cases, the behavior may also be quasi-periodic or even chaotic.
24 June – Dunedin Airport receives its first international flight—a Jetstar flight from Gold Coast Airport—since the start of the COVID-19 pandemic in 2020. 25 June – Nelson Hospital switches from coal to landfill gas as part of a nationwide decarbonisation shift. 26 June: A state of emergency is declared in the Wairau-Awatere Ward of Marlborough due to heavy rain. 32 Māori land trusts (representing over 150,000 landowners, hapu (sub-groups) and iwi (tribes) file legal proceedings against the New Zealand Crown at the High Court urging the Government to stop the degradation of fresh water, honour the Treaty of Waitangi and Māori rights over water and geothermal resources. The New Zealand Government passed legislation designating the Independent Children's Monitor as an independent Crown entity, dissolving the Children and Young People's Commission and reinstating the Children's Commissioner. 27 June: A state of emergency is declared in Nelson and Tasman due to heavy rain and flooding . Residents of parts of Spring Creek are asked to evacuate in response to concerns that heavy overnight rain could cause the Wairau River to flood. New Zealand First list Member of Parliament Tanya Unkovich resigns to concentrate on work in the private sector. 28 June – A tornado in Waitara damages 11 homes. 29 June — The Government's sentencing reforms, which reduces sentencing discounts and encourages cumulative sentencing, comes into effect. 30 June – Oji Fibre Solutions ceases paper production operations at its Kinleith Mill in Tokoroa, affecting 230 jobs.
Sources: en.wikipedia.org
=== Non-inhibitory roles === Non-inhibitory extracellular serpins also perform a wide array of important roles. Thyroxine-binding globulin and transcortin transport the hormones thyroxine and cortisol, respectively. The non-inhibitory serpin ovalbumin is the most abundant protein in egg white. Its exact function is unknown, but it is thought to be a storage protein for the developing foetus. Heat shock serpin 47 is a chaperone, essential for proper folding of collagen. It acts by stabilising collagen's triple helix whilst it is being processed in the endoplasmic reticulum. Some serpins are both protease inhibitors and perform additional roles. For example, the nuclear cysteine protease inhibitor MENT, in birds also acts as a chromatin remodelling molecule in a bird's red blood cells.
Bush publicly condemned Kim Jong-il of North Korea and identified North Korea as one of three states in an "axis of evil". He said that "the United States of America will not permit the world's most dangerous regimes to threaten us with the world's most destructive weapons." Within months, "both countries had walked away from their respective commitments under the U.S.–DPRK Agreed Framework of October 1994." North Korea's October 9, 2006, detonation of a nuclear device further complicated Bush's foreign policy, which centered for both terms of his presidency on "[preventing] the terrorists and regimes who seek chemical, biological, or nuclear weapons from threatening the United States and the world". Bush condemned North Korea's position, reaffirmed his commitment to "a nuclear-free Korean Peninsula", and said that "transfer of nuclear weapons or material by North Korea to states or non-state entities would be considered a grave threat to the United States", for which North Korea would be held accountable. On May 7, 2007, North Korea agreed to shut down its nuclear reactors immediately pending the release of frozen funds held in a foreign bank account. This was a result of a series of three-way talks initiated by the United States and including China. On September 2, 2007, North Korea agreed to disclose and dismantle all its nuclear programs by the end of 2007. By May 2009, North Korea had restarted its nuclear program and threatened to attack South Korea.
In his book TiHKAL (Tryptamines I Have Known and Loved), Alexander Shulgin lists the same dose range of 10 to 20 mg orally and duration of 3 to 6 hours for psilocin, psilocybin, and 4-AcO-DMT. Another publication gave a 4-AcO-DMT dose range of 10 to 15 mg orally, with a typical dose of 12.5 mg orally, and a duration of about 5 to 8 hours. A further source gave a dose range for the drug of 5 to 30 mg orally, an onset of 15 to 40 minutes, and a duration of 4 to 7 hours. 4-AcO-DMT is a prodrug of psilocin similarly to psilocybin and its effects are reported to be similar or identical to those of psilocybin and psilocybin-containing mushrooms. However, it is said to produce less nausea and body load than psilocybin-containing mushrooms. The drug is also often described as having a faster onset and shorter duration than psilocybin. 4-AcO-DMT exposure results in modestly lower peripheral plasma concentrations of psilocin by weight than psilocybin in animals when they are given at equimolar doses. Specific effects of 4-AcO-DMT have been reported to include psychedelic visuals, closed-eye imagery, synesthesia, insights, disembodiment, euphoria, feelings of bliss and unity, oceanic boundlessness, ego dissolution, sedation, cognitive impairment, and spiritual experiences, among others. Adverse effects have been reported to include psychological side effects such as anxiety, paranoia, and low mood as well as gastrointestinal side effects such as nausea and vomiting.
Sources: en.wikipedia.org
Liquid chromatography–mass spectrometry is common for identity and purity checks. High-performance liquid chromatography with ultraviolet detection can also be used. Both methods require a suitable reference standard.
The solid is usually kept desiccated at -20 °C or lower and protected from light. Stock solutions are aliquoted to limit freeze–thaw cycles. Aqueous solutions are not generally recommended for long-term storage.
Laws differ by country and by intended use. It is not an approved medicine, and many vendors sell it as a research chemical. Purchasers are responsible for confirming local restrictions.
The most common approach is liquid chromatography-tandem mass spectrometry, often after extraction from blood, urine, or tissue. Ultraviolet detection and nuclear magnetic resonance spectroscopy are used mainly for reference material characterization. Isotope-labeled internal standards improve accuracy.